CDDP Group | THD group | P | |||
---|---|---|---|---|---|
% of patients | Baseline | 12 months | Baseline | 12 months | |
ACEi | 34 | 33 | 50 | 48.3 | n.s |
ARBs | 24 | 26 | 30 | 21 | n.s |
Calcium channel blockers | 28.9 | 27.3 | 30 | 17 | n.s |
Calcium carbonate | 59 | 60 | 76.6 | 72.4 | n.s. |
Sevelamer or Lanthanum carbonate | 0 | 12a | 0 | 41c | <0.03 |
Paricalcitol | 0 | 12b | 0 | 17.2b | n.s. |
Cinacalcet | 0 | 6b | 0 | 24c | <0.04 |
Calcitriol | 45 | 42 | 46.7 | 45 | n.s. |
Kayexalate | 21 | 21 | 20 | 38 | n.s. |
Allopurinol | 48.6 | 54 | 33.3 | 13.8a | 0.01 |
Statins | 37 | 33 | 26.7 | 24 | n.s |
Polyunsaturated fats | 13 | 9 | 10 | 17 | n.s. |